ArticlePakistan journal of medical sciences2025
Primary Extraosseous Central Nervous System Ewing Sarcoma in Children: A Rare Case Series from a Major Public Neuro-Oncology Center in Pakistan.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary extraosseous central nervous system Ewing Sarcoma (CNS-EES) in children is a rare disorder, and this study aimed to document the experience of dealing with these rare pathologies of CNS in our center. This ambidirectional descriptive case series included all consecutive cases of CNS-EES in children under the age of 16 years presenting to the The Children's Hospital Lahore, Pakistan, from January 2023 to December 2024. During the 24-month study period, 4 out of 139 incident CNS tumor cases at our center were diagnosed as primary CNS-EES, corresponding to a proportional incidence of 2.9% (95% CI: 1.1-7.2%). The median age of presentation was 8.5 years, with equal gender distribution. Pain was the first presenting symptom, with a median symptom duration of 5.75 weeks. Half of the cases presented with a cerebral hemispheric mass and half with a spinal mass. The median event-free survival was 4.5 weeks with a survival rate of 25%. All cases were diagnosed based on a round blue cell morphology with a positive NKX2.2. Primary CNS-EES is not very infrequent in our population, with possible parietal lobe predilection and association with cancer predisposition syndrome. In resource-limited settings, NKX2.2 might serve as a fair substitute to diagnose CNS-EES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.